Previous Article | Next Article ![]()
Journal of Bacteriology, February 1999, p. 949-956, Vol. 181, No. 3
Alexander Silberman Institute of Life
Sciences, Hebrew University, Jerusalem 91904, Israel
In this report we describe the functional expression of EmrE, a
110-amino-acid multidrug transporter from Escherichia coli, in the yeast Saccharomyces cerevisiae. To allow for
phenotypic complementation, a mutant strain sensitive to a series of
cationic lipophilic drugs was first identified. A hemagglutinin
epitope-tagged version of EmrE (HA-EmrE) conferring resistance to a
wide variety of drugs, including acriflavine, ethidium, methyl
viologen, and the neurotoxin 1-methyl-4-phenylpyridinium
(MPP+), was functionally expressed in this strain. HA-EmrE
is expressed in yeast at relatively high levels (0.5 mg/liter), is
soluble in a mixture of organic solvents, and can be functionally
reconstituted in proteoliposomes. In bacterial cells, EmrE removes
toxic compounds by active transport through the plasma membrane,
lowering their cytosolic concentration. However, yeast cells expressing
HA-EmrE take up 14C-methyl viologen as well as control
cells do. Thus, we investigated the basis of the enhanced resistance to
the above compounds. Using Cu2+ ions or methylamine, we
could selectively permeabilize the plasma membrane or deplete the
proton electrochemical gradients across the vacuolar membrane,
respectively. Incubation of yeast cells with copper ions caused an
increase in 14C-methyl viologen uptake. In contrast,
treatment with methylamine markedly diminished the extent of uptake.
Conversely, the effect of Cu2+ and methylamine on a plasma
membrane uptake system, proline, was essentially the opposite: while
inhibited by the addition of Cu2+, it remained unaffected
when cells were treated with methylamine. To examine the intracellular
distribution of HA-EmrE, a functional chimera between HA-EmrE and the
green fluorescent protein (HA-EmrE-GFP) was prepared. The pattern of
HA-EmrE-GFP fluorescence distribution was virtually identical to that
of the vacuolar marker FM 4-64, indicating that the transporter is
found mainly in this organelle. Therefore, HA-EmrE protects yeast cells
by lowering the cytoplasmic concentrations through removal of the toxin
to the vacuole. This novel way of detoxification has been previously
suggested to function in organisms in which a large vacuolar
compartment exists. This report represents the first molecular
description of such a mechanism.
Multidrug transporters (MDTs) are
proteins that recognize a wide substrate range with relatively high
affinity and remove the substrates from the cytoplasm in an
energy-dependent process. Since many of the substrates happen to be
toxic compounds, the MDTs frequently have been associated with
multidrug resistance, a phenomenon that poses a serious threat to the
treatment of resistant cancers and infectious diseases. Based on
primary amino acid sequence similarities, five different families of
MDTs have been identified. The MiniTEXANs or SMR family includes more
than 40 proteins in eubacteria, a few of which have been studied in
detail. One of them, EmrE, is an Escherichia coli MDT which
confers resistance to a wide variety of toxicants by actively
exchanging them with hydrogen ions (15, 26, 29, 34). EmrE is
a highly hydrophobic 12-kDa protein that has been purified by taking
advantage of its unique solubility in organic solvents. After
solubilization and purification, the protein retains its ability to
transport, as judged from the fact that it can be reconstituted in a
functional form (45). Hydrophobicity analysis of the
sequence yielded four putative transmembrane domains of similar sizes.
Results from transmission Fourier transform infrared measurements agree
remarkably well with this hypothesis and yielded MDTs are used in various gene therapy projects for selection of
transfected cells and to promote gene amplification (24). EmrE is a relatively simple H+-driven MDT; it is a small
polypeptide, and no known posttranslational modifications are required
for its function. We therefore explored the possibility that it may
serve as a versatile gene for biotechnology projects.
Saccharomyces cerevisiae provides a good model system to
study transport processes in more complex organisms because of the vast
genetic tools available and its wide use in heterologous expression of
membrane proteins. In this work, HA-EmrE, a hemagglutinin (HA)
epitope-tagged version of EmrE, was functionally expressed in S. cerevisiae. Yeast cells expressing HA-EmrE exhibit enhanced resistance to a wide variety of cytotoxic compounds. Since overall drug
uptake levels were similar in HA-EmrE-expressing and control cells, we
investigated the mode of protection exerted in yeast by the
transporter. The subcellular protein distribution was determined by
using a fluorescent dye specific for the vacuolar membrane and a
functional chimera between the transporter and green fluorescent protein (GFP). Our results strongly suggest that HA-EmrE protects yeast
cells by sequestration of the cytotoxic compounds in the yeast vacuole.
This novel way of detoxification might be found in other organisms in
which large vacuolar compartments exist.
Materials.
14C-methyl viologen (paraquat) was
from Sigma. [3H]proline (26 Ci/mmol) was from Amersham,
and FM 4-64 was from Molecular Probes. Other reagents were from
commercially available sources.
Strains.
E. coli DH5 Media.
Yeast strains were grown in standard media. Complete
medium (YPD) contained 1% yeast extract, 2% Bacto Peptone (both from Difco), and 2% glucose or 2% glycerol. Minimal medium (SD; 0.67% yeast nitrogen base without amino acids [Difco] and 2% glucose) was
supplemented according to auxotrophic requirements as described in
reference 16. Yeast cells were transformed by the
method of Elble (11).
Plasmids.
Plasmid pNKY85 (1) was digested with
BglII and used to transform YAE65 and YHE4 from LEU2
ura3 to leu2::URA3. Transformed colonies were picked and tested for auxotrophicity to leucine in
uracil-lacking media. BFG-1 (2µm, 3-phosphoglycerate kinase promoter
and terminator, LEU2) contains an internal ATG followed by
three copies of the HA epitope (41) separated by a
BamHI site (38). The codons in this epitope favor
efficient translation since they are among those preferred by yeast
(4).
Cloning procedures.
The open reading frame of EmrE was
amplified by PCR from pKK56 (45), using as the sense primer
EP485-3 (5'-TTCGAAGCTTGGATCCATGAACCCTTATATTTATCTTG) and as
the antisense primer RP
(5'-CCGAATTCTCGAGTTAATGTGGTGTGCTGCTTCGTGAC), and digested
with BamHI and XhoI. The DNA segment was ligated with BFG-1, creating BFG-1/HA-EmrE. In this way, EmrE is inserted in
frame at the BamHI site and as a result contains 24 additional amino acids at the N terminus bearing two copies of the HA
epitope (YPYDVPDYA) (Fig. 1A).
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
EmrE, a Small Escherichia coli Multidrug
Transporter, Protects Saccharomyces cerevisiae from Toxins
by Sequestration in the Vacuole
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
-helical estimates
of 78 and 80% for EmrE in chloroform-methanol and 1,2-dimyristoyl
phosphocholine, respectively (2). That EmrE is
functional as a homo-oligomer is suggested by coreconstitution
experiments of the wild-type protein with three different inactive
mutants in which negative dominance has been observed (46).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References
(17) was used for
propagation of recombinant plasmids. The S. cerevisiae
strains used in this study were YAE65 (MATa ade2-119
ilv1-92 trp5-b sge1 ura3
5) and YHE4 (MATa ade2-119 ilv1-92 trp5-b ura3
5) (9, 10) (kindly
supplied by C. Senstag, University of Zurich) as well as BWT-1
(mat
GAL his3 lys2 ura3 leu2 trp1 met10; from the A. Levitzki lab stock).

View larger version (50K):
[in a new window]
FIG. 1.
HA-EmrE protects bacteria and yeast cells from a wide
range of cytotoxic compounds. (A) Diagrammatic presentation of the
generation of HA-EmrE. EmrE was inserted in frame at the
BamHI site of the BFG-1 vector, creating the epitope-tagged
HA-EmrE. HA-EmrE contains 24 additional amino acids at the N-terminus
comprising two repeats of the HA epitope (YPYDVPDYA). (B) HA-EmrE, like
the wild-type EmrE, confers resistance to bacterial cells.
Five-microliter aliquots of logarithmic dilutions (1:102 to
1:107) from an overnight culture were spotted on LB plates
in the absence (control) or presence of either 0.2 mM acriflavine, 0.2 mM methyl viologen, or 0.5 mM ethidium. (C) YAE65 is an S. cerevisiae strain particularly sensitive to MPP+.
Overnight cultures were tested for susceptibility to the toxin
MPP+. In comparison to the yeast wild-type strain BWT-1,
YHE4 shows an increased sensitivity surpassed only by that of the
extremely sensitive isogenic strain YAE65. (D) Yeast cells expressing
HA-EmrE show an increased resistance to pleiotropic drugs. YAE65 cells
were grown overnight in minimal medium. Serial dilutions (1:1 to
1:105) were performed in sterile water, and 5-µl
suspensions were spotted on YPD plates containing the indicated drug
concentrations. After 3 days of incubation at 30°C, the plates were
photographed.
Drug sensitivity assays. E. coli JM109 (43) was transformed with pKK/HA-EmrE, pKK/EmrE (pKK56) (45), or pKK223-3 (mock vector). After overnight growth at 37°C, the culture was diluted serially 10-fold and 5-µl aliquots of the suspensions were spotted on LB plates in the presence or absence of the various compounds at the indicated concentrations. After 24 h of growth, the plates were photographed. Similarly, yeast strain YAE65 transformed with the corresponding plasmids was grown in liquid minimal medium to late log phase. Five-microliters aliquots of logarithmic dilutions from these cultures were spotted on YPD or YPG plates with various concentrations of the tested drug. YPD plates were incubated at 30°C for 2 to 3 days.
Membrane purification.
Membranes of yeast cells were
prepared by the glass beads protocol (12) modified as
follows. Cells were grown on minimal medium to early logarithmic phase,
harvested, and washed once with sterile distilled water and once with
ice-cold lysis buffer containing 140 mM NaCl 10 mM K-HEPES (pH 7.4), 10 mM MgCl2, 10% glycerol, and 10 mM
-mercaptoethanol. The
pellet was resuspended with 2 ml per g of cell pellet in lysis buffer
supplemented with a cocktail of protease inhibitors (0.2 mM
phenylmethylsulfonyl fluoride, 1 µM pepstatin, 1 µM aprotinin, 5 µM leupeptin, and 10 µM chymostatin). An equal volume of
acid-washed glass beads was added, and the suspension was vortexed in a
cold room six times for 30 s each. The lysate was centrifuged at
4°C for 5 min at 5,000 × g to discard whole cells.
The supernatant was then ultracentrifuged for 45 min at
200,000 × g, and the pellet was resuspended in a
minimal volume of lysis buffer supplemented with antiproteases. The
membrane suspension was immediately frozen in liquid nitrogen and
stored at
70°C until thawed for further manipulations.
Western blotting. Membrane lysates were mixed with an equal volume of protein sample buffer, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 16% Tricine gels as described elsewhere (33). The protein was transferred to a polyvinylidene difluoride membrane (Millipore) by using a semidry blotter for 45 min at 1 mA/cm2. Transfer buffer contained 48 mM glycine, 25 mM Tris-HCl (pH 8.3), and 10% methanol. The membrane was then blocked for 1 h in 1% blocking solution (Boehringer Mannheim) in TBS-T (137 mM NaCl, 50 mM Tris-HCl [pH 7.5], 0.05% Tween 20). The blot was then incubated at least for 2 h with 1:5,000 dilution of monoclonal antibody against the HA epitope (12CA5; BAbCo, Berkeley, Calif.). After five washes with TBS-T, the blot was incubated with anti-mouse secondary antibody (Boehringer Mannheim), and developed as recommended in the protocol for the Boehringer Mannheim chemiluminescence Western blotting kit.
Extraction and reconstitution of HA-EmrE from yeast
membranes.
The method used is modified from one described
elsewhere (45). In brief, 27-µl aliquots of E. coli phospholipids (50 mg/ml) were added to 400 µl of yeast
membranes (10 mg/ml) and mixed with 6 ml of chloroform- to methanol
(1:1). After 30 min on ice, 1 ml of water was added, and the mixture
was vortexed and centrifuged at 4°C for 5 min at 5,000 × g. The upper phase was removed, and the lower phase was dried with
argon. The pellet was resuspended in 80 µl of 0.18 M
NH4Cl-15 mM Tris-HCl (pH 7.0). The mixture was divided in
aliquots and frozen at
70°C.
Transport of 14C-methyl viologen in proteoliposomes. Transport was as described in reference 45. In brief, before the transport assay, the proteoliposome suspension was thawed and sonicated in a bath-type sonicator for a few seconds until clear. Then 3 µl of this suspension was diluted in 200 µl of an ammonium-free medium containing 140 mM KCl, 10 mM Tricine, and 5 mM MgCl2 (pH 8.5) in the presence of 70 µM 14C-methyl viologen (150 nCi/assay) and the correspondent tracers and inhibitors as indicated for each experiment. At given times, the reaction was stopped by dilution with 2 ml of ice-cold solution without the radioactive substrate, filtering through Schleicher & Schuell filters (0.2-µm pore size), and washing with an additional 2 ml of solution. The radioactivity on the filters was assessed by liquid scintillation. In each experiment, a control reaction with 5 µM nigericin was used to subtract the nonspecific radioactivity.
Transport in whole cells. The method used is essentially as described by Kitamoto et al. (21, 27). Briefly, cells were grown to the early logarithmic phase in minimal glucose medium, counted, harvested, and washed twice with sterile distilled water. Cells were then resuspended to a density of 1.5 × 109/ml in buffer B (0.6 M sorbitol, 10 mM glucose, 20 mM morpholineethanesulfonic acid-Tris [pH 6.0]) and incubated for 30 min at 30°C, in the absence or presence of 0.5 mM CuSO4 and/or 10 mM methylamine. The suspension was diluted 10-fold in transport buffer with the correspondent tracers in the presence of 10 µCi of 14C-methyl viologen or [3H]proline per ml. Aliquots of 100 µl were withdrawn at the indicated times, diluted in 3 ml of ice-cold buffer B and rapidly filtered through HAWP filters (pore size, 0.45 µm; Millipore). After the filters were washed three times with 3 ml of ice-cold transport buffer and briefly dried, radioactivity was assessed by liquid scintillation. Each experiment was repeated independently at least three times.
Vacuolar staining with FM 4-64. Cells were grown in minimal medium to early logarithmic phase, harvested, and resuspended to an optical density at 600 nm (OD600) of 5 in minimal medium supplemented at 10 µg/ml with the lipophilic styryl dye N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenyl-hexatrienyl) pyridinium dibromide (FM 4-64) (40). After 60 min of incubation at 30°C, cells were spun, washed twice, and resuspended at an OD600 of 0.2 for at least 1 h in minimal medium (chase). For confocal microscopy, an aliquot of the suspension was spun resuspended in a minimal volume of growth medium, mixed with an equal volume of 2.6% low-melting-point agarose, poured on a slide, sealed, and immediately visualized in a confocal microscope.
Scanning laser confocal microscopy. A Bio-Rad MRC-1024 confocal scanhead coupled to a Zeiss Axiovert 135M inverted microscope was used to acquire images of the stained cells, with a 63× oil objective (numerical aperture, 1.4). Excitation light was provided by a 100-mW air-cooled argon ion laser run in the multiline mode. The excitation wavelength of 488 nm was selected with a suitable interference filter. The relative excitation power level was set with either a 3 or 1% neutral density filter. The fluorescence emission was split between three channels with two dichroic mirrors (555DRLP [50% point at 550 nm] and 605DRHP [50% point at 605 nm]). GFP emission was detected on the short-wavelength side of the first dichroic mirror, through an HQ525/40 bandpass filter (525 ± 20 nm). The confocal aperture was 2.5 to 3.0mm. There was no detectable bleedthrough of FM 4-64 to this channel. FM 4-64 emission was detected on the long-wavelength side of the second dichroic mirror, through an HQ655/90 bandpass filter (655 ± 45 nm). The confocal aperture was 4.0 to 4.5 mm. There was some detection of GFP emission in the FM 4-64 channel, but it was weaker than the FM 4-64 emission under the conditions of these experiments. The maximum bleedthrough was estimated to be no more than 15%.
| |
RESULTS |
|---|
|
|
|---|
Epitope tagging of EmrE. EmrE is a miniature MDT from E. coli. It is a 110-amino-acid-long polypeptide with four putative transmembrane domains. Since it lacks significant hydrophilic domains, its immunogenicity is low and it is difficult to raise antibodies against it, even after repeated injections of pure EmrE protein to rabbits (unpublished observations). To identify the transporter by immunological techniques, EmrE was tagged with the HA epitope (YPYDVPDYA). For this purpose, an oligonucleotide was engineered to allow for in-frame insertion of the emrE gene in the BamHI site at the multicloning site of the yeast expression plasmid BFG1-1, creating HA-EmrE (Fig. 1A). As a result, HA-EmrE has 24 additional amino acids at the N terminus of the protein bearing two copies of the HA epitope.
HA-EmrE confers resistance to E. coli cells as well as the wild-type EmrE does. To determine whether addition of the double epitope has an effect on EmrE function, we assessed the resistance conferred to E. coli cells. E. coli JM109 cells transformed with either pKK/EmrE, pKK/HA-EmrE, or pKK223-3 (mock vector) were grown on LB plates in the absence or presence of various drugs. As shown in Fig. 1B, cells expressing HA-EmrE could grow in the presence of 0.2 mM acriflavine, 0.2 mM methyl viologen, or 0.5 mM ethidium as well as cells expressing the wild-type EmrE. In contrast, cells transformed with the vector alone (pKK223-3) grew only on the control plate (LB supplemented with 50 µg of ampicillin per ml). Identical conclusions were reached when resistance was assessed in liquid media or by measurements of the halo of growth inhibition around filters soaked with concentrated solutions of the above compounds (not shown). The results demonstrate that the epitope-tagged version of EmrE retains the ability to protect the cells and may serve for future studies in which immunological methods are required.
Characterization of a strain sensitive to multiple drugs. To test phenotypic complementation of an MDT, it was necessary to use an S. cerevisiae strain sensitive to a wide variety of toxicants. We screened a wide variety of mutants and found one which displayed the desired phenotype. The strain chosen was YAE65, an sge1 null mutant that was selected for its sensitivity to crystal violet and harbors an additional unidentified mutation that increases its sensitivity (9, 10). These findings are demonstrated in experiments in which serial dilutions of overnight cultures were plated on YPD plates containing increasing concentrations of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+). The results in Fig. 1C reveal the high sensitivity of strain YAE65 to MPP+ compared to the resistance shown by wild-type strain BWT-1. Whereas at 0.75 mM MPP+ the growth of strain YAE65 is impaired, wild-type BWT-1 grows at 1.5 mM MPP+ practically as well as it grows in its absence. Use of glycerol as the sole carbon source enhances the effectiveness of MPP+. At MPP+ concentrations as low as 0.25 mM in YPGly plates, the growth of BWT-1 is almost nil (not shown). The difference may stem from the fact that the suggested MPP+ site of action is the mitochondrial respiratory chain (31). In YPGly medium, cells depend entirely on the integrity of the mitochondria to support their growth, whereas in YPD growth might be sustained by the glycolytic pathway when mitochondria fail. The overall growth was significantly slower with glycerol than with glucose. The experiments shown below were carried out on glucose-containing media.
Functional expression of HA-EmrE in yeast cells. As explained earlier, EmrE was inserted in BFG-1, a vector used for expression in S. cerevisiae. BFG-1 is a 2µm plasmid which uses the strong and constitutive 3-phosphoglycerate kinase promoter and terminator (37). The first 24 amino acids of HA-EmrE, corresponding to the appended sequence, are encoded mainly by codons used in highly expressed yeast proteins (Codon Bias Index) (4). This allows for high levels of expression of otherwise unexpressed heterologous proteins (unpublished observations). In the specific case of HA-EmrE, relatively high levels of expression are achieved; it is possible to produce 0.5 mg of HA-EmrE per liter of minimal medium. We examined whether the expression of HA-EmrE causes sensitive yeast cells to display increased resistance to pleiotropic drugs. In the example of such an experiment shown in Fig. 1D, YAE65 cells transformed with BFG-1/HA-EmrE grew better in the presence of toxicants than did control (BFG-1) cells. As shown in Fig. 1D, expression of HA-EmrE in YAE65 cells confers resistance to a wide variety of toxicants: increased resistance to MPP+ (1.5 mM), to methyl viologen (3 mM), and to ethidium (75 µM). In experiments in which the OD600 of overnight cultures grown in the presence of cytotoxic compounds was measured, the results were essentially similar: only yeast cells expressing HA-EmrE were resistant to the toxic effects of the compounds tested. We conclude that HA-EmrE is functionally expressed in S. cerevisiae.
HA-EmrE is soluble in a mixture of chloroform and methanol.
To
identify HA-EmrE in total cell membranes prepared from yeast cells, we
used a monoclonal antibody (12CA5) against the HA epitope. For Western
blots, we used as a negative control membranes from cells transformed
with the vector (BFG-1) alone. As shown in Fig.
2A, HA-EmrE appears mainly as a single
band of ~14 kDa (lane 2); in contrast, no immunoreactivity was
detected in the control sample (lane 1). Wild-type EmrE can be
extracted with a 1:1 mixture of chloroform and methanol (yielding what
we refer to as C:M extracts) (45). Therefore, we checked
whether HA-EmrE retains this unusual property. Indeed, HA-EmrE is also
quantitatively extracted with organic solvents (Fig. 2, lane 5).
Noteworthy, the additional 24 amino acids include four negative charges
(corresponding to four aspartic acids), changing the overall protein
charge from +2 to
2, yet, the transporter is still soluble in the
above mixture.
|
HA-EmrE transport activity can be reconstituted in vitro.
HA-EmrE expressed in yeast is also functional in vitro, as demonstrated
by the fact that the extracted and highly purified protein can be
reconstituted in proteoliposomes. In this system, HA-EmrE catalyzes
pH driven accumulation of 14C-methyl viologen against
its concentration gradient. Proteoliposomes prepared from C:M extracts
of control membranes (BFG-1) showed no uptake activity. In contrast,
those prepared from extracts of membranes containing HA-EmrE showed
100-fold-higher uptake activity (Fig. 2B). We also determined whether
the recombinant protein has the same specificity range as the wild
type. We measured the ability of competitors to inhibit the uptake of
14C-methyl viologen in proteoliposomes and found that the
50% inhibitory concentrations of each tested substrate (acriflavine
[10 µM] and ethidium [1.27 µM] were similar to those measured
for the wild-type transporter (45). An example of such an
assay is shown in Fig. 2C, where ethidium totally inhibited
14C-methyl viologen uptake in a concentration-dependent manner.
HA-EmrE protects yeast cells by intracellular compartmentalization
of the toxins.
EmrE protects bacterial cells against cytotoxic
compounds by active extrusion of the offending compounds across the
plasma membrane, thereby lowering their concentration near their target sites. An electrochemical gradient of protons, of the proper direction and magnitude, that may sustain HA-EmrE activity is found also across
the plasma membrane of yeast cells. Hence, we investigated whether a
similar HA-EmrE-driven removal mechanism protects the resistant cells.
Using a rapid filtration method, we measured the uptake of
14C-methyl viologen in whole cells. As shown in Fig.
3A, the content of 14C-methyl
viologen in HA-EmrE is actually slightly higher than the uptake level
of control cells. Based on these results, we set up experiments to
investigate the mechanism by which cells expressing HA-EmrE display an
increased resistance even though they absorb the same extent of
toxicants. Anraku and collaborators (21, 27) have shown that
it is possible to selectively permeabilize the plasma membrane by the
addition of Cu2+ ions to cells resuspended in a medium of
low ionic strength. The Cu2+ permeabilization technique
allows the specific extraction of cytosolic pools of ions, amino acids,
and other metabolites. We measured the uptake of 14C-methyl
viologen in the presence of 0.5 mM CuSO4 and found that whereas in control cells the uptake increased only slightly,
HA-EmrE-expressing cells showed a twofold increase in the magnitude of
uptake (Fig. 3B). A possible explanation for this phenomenon is that
HA-EmrE is located in a subcellular compartment in which
µH+ is generated across its membrane and serves
as the driving force for active sequestration of the toxicants. The
plasma membrane constitutes a diffusion barrier for methyl viologen;
hence, the addition of Cu2+ abolishes this restriction and
allows an enhanced intracellular HA-EmrE-mediated uptake. In line with
this contention, Cu2+ has no effect on the activity of the
purified protein reconstituted in proteoliposomes. It is possible to
diminish the magnitude of H+ gradients by using weak bases
such as ammonia or other amines such as methylamine (14). We
determined the effect of 10 mM methylamine on the uptake of
14C-methyl viologen and found that it causes a drastic
reduction in the extent of methyl viologen incorporation. The dramatic
results were quantitatively similar for control and HA-EmrE-expressing cells (Fig. 3B). Similar results were achieved with 100 µM carbonyl cyanide m-chlorophenylhydrazone, a proton ionophore (not
shown). For a transport system located in the plasma membrane, the
effects of Cu2+ and methylamine are expected to be
essentially the opposite. Indeed, when we tested the influence of the
above compounds on the uptake of [3H]proline, the inverse
effect was found. Proline is transported by plasma membrane
transporters and stored in the cytosol (21, 32). As shown in
Fig. 3C, we found no significant differences between the cells in the
uptake of proline. As expected for a plasma membrane transport system,
treatment with methylamine did not change the transport values
significantly. In contrast, Cu2+ addition abolished the
uptake of [3H]proline (Fig. 3D). Taken as a whole, the
results of both transport experiments strongly favor the hypothesis
that HA-EmrE catalyzes the sequestration of toxicants on subcellular
acidic compartments.
|
HA-EmrE-GFP is located at the vacuolar membrane.
Various
organelles may fulfill the acidic requirements necessary for HA-EmrE
activity, among them secretory vesicles, endosomes, and the vacuole. To
examine the intracellular localization of the transporter, we
constructed a fusion of HA-EmrE with GFP. This fusion protein is fully
functional, as judged by its ability to confer resistance to
MPP+ (Fig. 4A), acriflavine,
ethidium, and methyl viologen (not shown). This protein is expressed at
approximately the same levels as HA-EmrE (Fig. 2A, lane 4). We also
detected a minor band of approximately ~16 kDa, probably a result of
some proteolysis occurring in the membrane isolation process. As
expected from the large hydrophilic tail attached to HA-EmrE, it is not
extractable into organic solvents (Fig. 2A, lane 7). In contrast,
HA-EmrE II, a protein created for the subsequent insertion of GFP, is
soluble in the above mixture (Fig. 2A, lane 6). HA-EmrE II has a total
protein charge of
3, as it contains two additional amino acids,
glutamate and phenylalanine, at the C terminus.
|
| |
DISCUSSION |
|---|
|
|
|---|
The evidence presented in this paper demonstrates that EmrE protects yeast cells by sequestration of the toxicants in the yeast vacuole. HA-EmrE expression in YAE65, an S. cerevisiae strain particularly sensitive to lipophilic cations (9, 10), caused an increased resistance to a variety of cytotoxic compounds. However, control and HA-EmrE-expressing cells took up comparable levels of 14C-methyl viologen. After selective permeabilization of the plasma membrane by using Cu2+ ions (27), HA-EmrE-expressing cells display an increased ability to take up methyl viologen. The increase might be explained by the elimination of a permeability barrier and the HA-EmrE-associated ability to remove toxicants from the cytoplasm to acidic intracellular compartments. Transport from the cytoplasm reduces the concentration of noxious chemicals near their targets, and cells become resistant. To test the role of the proton gradient across the vacuolar membrane, we used methylamine, a weak base known to impair the magnitude of those gradients (14). Methylamine completely abolished the uptake of 14C-methyl viologen and, notably, also reduced the extent of 14C-methyl viologen uptake in control (BFG-1) cells. The results may reflect the activity of an existing endogenous H+-driven transport system, which extrudes its substrates into subcellular acidic compartments. As a control for the method used, we tested the effects of Cu2+ and methylamine on a plasma membrane transport system. Proline is taken up by a specific permease (PUT4) (39). As expected, whereas methylamine did not inhibit [3H]proline uptake, addition of Cu2+ drastically diminished the extent of this uptake. These results imply that the data presented here reflect genuine HA-EmrE-mediated toxin sequestration into subcellular compartments. Distribution of the HA-EmrE-GFP fluorescence closely resembled that of the fluorescent signal of FM 4-64. The results support the contention that although several intracellular membranes exist, HA-EmrE-GFP is found mainly in the tonoplast. Taking the results as a whole, we conclude that the mechanism of protection mediated by HA-EmrE is the active removal of cytotoxic compounds into the yeast vacuole.
Protection by compartmentation of toxicants seems to be widespread in organisms in which large vacuoles exist. The vacuole plays an important role in the detoxification and as a homeostatic mechanism to balance the cytosolic metal contents within the nontoxic range. It has been suggested that in yeast, compartmentalization is the mechanism underlying resistance to metals such as cadmium (23), nickel (19, 30), tellurium, iron and copper (36), chromium and selenium (13), and presumably cobalt and zinc (8). In plants, the lack of specific detoxification organs forces this organism to supply the cells with specific autonomous mechanisms of protection. Indeed, the vacuole has been suggested to provide a storage compartment for defense proteins and secondary metabolites (allelochemicals) (42) and to act as a transient storage compartment for further detoxification of heavy metals (47). Although the P-glycoprotein or MDR is the major protein conferring resistance to numerous cell types, some findings could not be explained solely by this mechanism. In several cases, the P-glycoprotein-mediated resistance was not correlated with decreased transport, suggesting that compartmentation may play a role in the resistance exhibited by these cells (5, 35). In fact, the multidrug resistance-related protein was shown to catalyze the sequestration of toxins into secretory vesicles (3, 6, 7).
Mammalian cells heterologously expressing a vesicular monoamine transporter (VMAT) become resistant to the neurotoxin MPP+ by intracellular compartmentalization of the toxin (25). Moreover, the VMAT family exhibits a distinct homology to bacterial MDTs. In addition, VMAT and EmrE have similar substrate specificities (44), suggesting that neurotransmitter transport may have evolved as a intracellular mechanism to protect the cells against possible toxicity of those compounds. Our results for methyl viologen uptake in the presence of methylamine suggest that a cryptic H+-driven transport system, similar to those found for metals, may exist in yeast for xenobiotics.
No consensus sequences have been defined for yeast vacuole proteins (22). It is interesting that the vast majority of a heterologous expressed membrane protein is sorted to the vacuolar membrane. Because of its small size and high expression levels, EmrE can provide a good model system for studying vacuolar targeting. We hereby show that a protein which acts as a toxin removal transporter in prokaryotes confers resistance by toxin sequestration into the vacuole of a eukaryotic cell.
| |
ACKNOWLEDGMENTS |
|---|
We thank Sharon Levy for the cloning of EmrE in BFG-1, Jeffrey Gerst (Weizmann Institute) for help with the FM 4-64 studies, and Aryeh Weiss for technical assistance with confocal microscopy.
This work was supported by grants from the Deutsche-Israeli Program, National Institutes of Health (NS16708), and Israel Science Foundation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem 91904, Israel. Phone: 972-2-6585992. Fax: 972-2-5634625. E-mail: shimons{at}leonardo.ls.huji.ac.il.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alani, E.,
L. Cao, and N. Kleckner.
1987.
A method for gene disruption that allows repeated use of URA3 selection in the construction of multiply disrupted yeast strains.
Genetics
116:541-545 |
| 2. | Arkin, I., W. Russ, M. Lebendiker, and S. Schuldiner. 1996. Determining the secondary structure and orientation of EmrE, a multi-drug transporter, indicates a transmembrane four helix bundle. Biochemistry 35:7233-7238[Medline]. |
| 3. | Benderra, Z., H. Morjani, A. Trussardi, and M. Manfait. 1998. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein. Int. J. Oncol. 12:711-715[Medline]. |
| 4. |
Bennetzen, J. L., and B. D. Hall.
1982.
Codon selection in yeast.
J. Biol. Chem.
257:3026-3031 |
| 5. | Bobichon, H., M. Colin, C. Depierreux, F. Liautaud-Roger, and J. C. Jardillier. 1996. Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J. Exp. Ther. Oncol. 1:49-61[Medline]. |
| 6. |
Breuninger, L. M.,
S. Paul,
K. Gaughan,
T. Miki,
A. Chan,
S. A. Aaronson, and G. D. Kruh.
1995.
Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
Cancer Res.
55:5342-5347 |
| 7. | Cleary, I., G. Doherty, E. Moran, and M. Clynes. 1997. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 53:1493-1502[Medline]. |
| 8. | Conklin, D. S., M. R. Culbertson, and C. Kung. 1994. Interactions between gene products involved in divalent cation transport in Saccharomyces cerevisiae. Mol. Gen. Genet. 244:303-311[Medline]. |
| 9. | Ehrenhofer-Murray, A. E., M. U. Seitz, and C. Sengstag. 1998. The Sge1 protein of Saccharomyces cerevisiae is a membrane-associated multidrug transporter. Yeast 14:49-65[Medline]. |
| 10. | Ehrenhofer-Murray, A. E., F. E. Wurgler, and C. Sengstag. 1994. The Saccharomyces cerevisiae SGE1 gene product: a novel drug-resistance protein within the major facilitator superfamily. Mol. Gen. Genet. 244:287-294[Medline]. |
| 11. | Elble, R. 1992. A simple and efficient procedure for transformation of yeasts. BioTechniques 13:18-20[Medline]. |
| 12. |
Franzusoff, A. J., and V. P. Cirillo.
1983.
Glucose transport activity in isolated plasma membrane vesicles from Saccharomyces cerevisiae.
J. Biol. Chem.
258:3608-3614 |
| 13. | Gharieb, M. M., and G. M. Gadd. 1998. Evidence for the involvement of vacuolar activity in metal(loid) tolerance: vacuolar-lacking and -defective mutants of Saccharomyces cerevisiae display higher sensitivity to chromate, tellurite and selenite. Biometals 11:101-106[Medline]. |
| 14. | Greenfield, N. J., M. Hussain, and J. Lenard. 1987. Effects of growth state and amines on cytoplasmic and vacuolar pH, phosphate and polyphosphate levels in Saccharomyces cerevisiae: a 31P-nuclear magnetic resonance study. Biochim. Biophys. Acta 926:205-214[Medline]. |
| 15. | Grinius, L., G. Dreguniene, E. B. Goldberg, C. H. Liao, and S. J. Projan. 1992. A staphylococcal multidrug resistance gene product is a member of a new protein family. Plasmid 27:119-129[Medline]. |
| 16. | Guthrie, C., and G. R. Fink (ed.). 1991. Methods in Enzymology, vol. 194. Academic Press, San Diego, Calif. |
| 17. | Hanahan, D. 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166:557-580[Medline]. |
| 18. | Heim, R., A. B. Cubitt, and R. Y. Tsien. 1995. Improved green fluorescence. Nature 373:663-664[Medline]. |
| 19. | Joho, M., Y. Ishikawa, M. Kunikane, M. Inouhe, H. Tohoyama, and T. Murayama. 1992. The subcellular distribution of nickel in Ni-sensitive and Ni-resistant strains of Saccharomyces cerevisiae. Microbios 71:149-159[Medline]. |
| 20. |
Kane, P. M.,
M. C. Kuehn,
I. Howald-Stevenson, and T. H. Stevens.
1992.
Assembly and targeting of peripheral and integral membrane subunits of the yeast vacuolar H(+)-ATPase.
J. Biol. Chem.
267:447-454 |
| 21. |
Kitamoto, K.,
K. Yoshizawa,
Y. Ohsumi, and Y. Anraku.
1988.
Dynamic aspects of vacuolar and cytosolic amino acid pools of Saccharomyces cerevisiae.
J. Bacteriol.
170:2683-2686 |
| 22. |
Klionsky, D. J.
1998.
Nonclassical protein sorting to the yeast vacuole.
J. Biol. Chem.
273:10807-10810 |
| 23. |
Li, Z. S.,
Y. P. Lu,
R. G. Zhen,
M. Szczypka,
D. J. Thiele, and P. A. Rea.
1997.
A new pathway for vacuolar cadmium sequestration in Saccharomyces cerevisiae: YCF1-catalyzed transport of bis(glutathionato)cadmium.
Proc. Natl. Acad. Sci. USA
94:42-47 |
| 24. | Licht, T., F. Herrmann, M. M. Gottesman, and I. Pastan. 1997. In vivo drug-selectable genes: a new concept in gene therapy. Stem Cells 15:104-111[Medline]. |
| 25. | Liu, Y., D. Peter, A. Roghani, S. Schuldiner, G. Prive, D. Eisenberg, N. Brecha, and R. Edwards. 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539-551[Medline]. |
| 26. |
Morimyo, M.,
E. Hongo,
H. Hama-Inaba, and I. Machida.
1992.
Cloning and characterization of the mvrC gene of Escherichia coli K12 which confers resistance against methyl viologen toxicity.
Nucleic Acids Res.
20:3159-3165 |
| 27. |
Ohsumi, Y.,
K. Kitamoto, and Y. Anraku.
1988.
Changes induced in the permeability barrier of the yeast plasma membrane by cupric ion.
J. Bacteriol.
170:2676-2682 |
| 28. | Prasher, D. C., V. K. Eckenrode, W. W. Ward, F. G. Prendergast, and M. J. Cormier. 1992. Primary structure of the Aequorea victoria green-fluorescent protein. Gene 111:229-233[Medline]. |
| 29. | Purewal, A. S., I. G. Jones, and M. Midgley. 1990. Cloning of the ethidium efflux gene from Escherichia coli. FEMS Microbiol. Lett. 68:73-76. |
| 30. | Ramsay, L. M., and G. M. Gadd. 1997. Mutants of Saccharomyces cerevisiae defective in vacuolar function confirm a role for the vacuole in toxic metal ion detoxification. FEMS Microbiol. Lett. 152:293-298[Medline]. |
| 31. | Ramsay, R. R., M. J. Krueger, S. K. Youngster, and T. P. Singer. 1991. Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same. Biochem. J. 273:481-484. |
| 32. |
Sato, T.,
Y. Ohsumi, and Y. Anraku.
1984.
Substrate specificities of active transport systems for amino acids in vacuolar-membrane vesicles of Saccharomyces cerevisiae. Evidence of seven independent proton/amino acid antiport systems.
J. Biol. Chem.
259:11505-11508 |
| 33. | Schagger, H., and G. von Jagow. 1987. Tricine-SDS PAGE for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368-379[Medline]. |
| 34. | Schuldiner, S., M. Lebendiker, and H. Yerushalmi. 1997. EmrE, the smallest ion coupled transporter, provides a unique paradigm for structure function studies. J. Exp. Biol. 200:335-341[Abstract]. |
| 35. | Shapiro, A. B., K. Fox, P. Lee, Y. D. Yang, and V. Ling. 1998. Functional intracellular P-glycoprotein. Int. J. Cancer 76:857-864[Medline]. |
| 36. | Szczypka, M. S., Z. Zhu, P. Silar, and D. J. Thiele. 1997. Saccharomyces cerevisiae mutants altered in vacuole function are defective in copper detoxification and iron-responsive gene transcription. Yeast 13:1423-1435[Medline]. |
| 37. | Tuite, M. F., M. J. Dobson, N. A. Roberts, R. M. King, D. C. Burke, S. M. Kingsman, and A. J. Kingsman. 1982. Regulated high efficiency expression of human interferon-alpha in Saccharomyces cerevisiae. EMBO J. 1:603-608[Medline]. |
| 38. | Tyers, M., G. Tokiwa, R. Nash, and B. Futcher. 1992. The Cln3-Cdc28 kinase complex of S. cerevisiae is regulated by proteolysis and phosphorylation. EMBO J. 11:1773-1784[Medline]. |
| 39. | Vandenbol, M., J. C. Jauniaux, and M. Grenson. 1989. Nucleotide sequence of the Saccharomyces cerevisiae PUT4 proline- permease-encoding gene: similarities between CAN1, HIP1 and PUT4 permeases. Gene 83:153-159[Medline]. |
| 40. |
Vida, T. A., and S. D. Emr.
1995.
A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast.
J. Cell Biol.
128:779-792 |
| 41. | Wilson, I. A., H. L. Niman, R. A. Houghten, A. R. Cherenson, M. L. Connolly, and R. A. Lerner. 1984. The structure of an antigenic determinant in a protein. Cell 37:767-778[Medline]. |
| 42. | Wink, M. 1993. The plant vacuole: a multifunctional compartment. J. Exp. Bot. 44:231-246. |
| 43. | Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103-199[Medline]. |
| 44. | Yelin, R., and S. Schuldiner. 1995. The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters. FEBS Lett. 377:201-207[Medline]. |
| 45. |
Yerushalmi, H.,
M. Lebendiker, and S. Schuldiner.
1995.
EmrE, an Escherichia coli 12-kDa multidrug transporter, exchanges toxic cations and H+ and is soluble in organic solvents.
J. Biol. Chem.
270:6856-6863 |
| 46. |
Yerushalmi, H.,
M. Lebendiker, and S. Schuldiner.
1996.
Negative dominance studies demonstrate the oligomeric structure of EmrE, a multidrug antiporter from Escherichia coli.
J. Biol. Chem.
271:31044-31048 |
| 47. |
Zenk, M. H.
1996.
Heavy metal detoxification in higher plants a review.
Gene
179:21-30[Medline].
|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»